You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)IBI362在糖尿病二期臨床研究完成首例受試者給藥
阿思達克 09-08 10:19
信達生物(01801.HK)公布,其胰高血糖素樣(月太)-1受體(GLP-1R)/胰高血糖素受體(GCGR)雙激動劑IBI362,於糖尿病受試者中的二期臨床研究完成首例受試者給藥。 該研究是一項在中國2型糖尿病患者中評價IBI362相對安慰劑及度拉糖(月太)療效和安全性的隨機、多中心的二期臨床研究。 集團醫學科學與戰略特病部執行總監錢鐳表示,IBI362作為胃泌酸調節素類似物,相較於傳統GLP-1R激動劑,激活GLP-1R和GCGR可獲得降糖和更好減重效果,並可能帶來包括肝臟脂肪含量、血壓、血脂等多重代謝改善,將全力推動IBI362在中國早日上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account